|
|
 | | | |
- close
- close
- close
- close
StreetInsider.com
Jan 25
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Cytokinetics+%28CYTK%29+Regains+Nasdaq+Listing+Compliance/8032837.html for the full story.
Benzinga
Jan 4
Comment
In a report published Friday, Piper Jaffray & Co. initiated coverage on Cytokinetics (NASDAQ: CYTK) with an Overweight rating and $4.00 price target.
Piper Jaffray noted, “We are initiating on Cytokinetics with an Overweight rating and $4...
StreetInsider.com
Jan 3
Comment
Accuray Incorporated (Nasdaq: ARAY) 20% LOWER; sees revenue of $72 million to $75 million, which is well below the consensus of $94.1 million. The company (1) manufacturing and supply related issues, which delayed contribution from new products...
Benzinga
Dec 18
Comment
Cytokinetics, Incorporated
(NASDAQ: CYTK), announced today that NASDAQ has approved the Company's request
to voluntarily transfer the listing of its shares of common stock from The
NASDAQ Global Market to The NASDAQ Capital Market. The transfer...
StreetInsider.com
Dec 7
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Cytokinetics+%28CYTK%29+Updates+on+Tirasemtiv+in+ALS+Patients/7931742.html for the full story.
StreetInsider.com
Nov 29
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Cytokinetics+%28CYTK%29%2C+Amgen+%28AMGN%29+Commence+Enrollment+in+ATOMIC-AHF/7910555.html for the full story.
Benzinga
Nov 27
Comment
Dawson James initiated coverage on Cytokinetics (NASDAQ: CYTK) with a Market Outperform rating and a $2 price target.
Dawson James said, "Although CYTK's programs are still relatively early, they are based on an understanding of the underlying...
Benzinga
Nov 26
Comment
Cytokinetics, Incorporated
(Nasdaq: CYTK) today announced positive data from a recently completed Phase
IIa "Evidence of Effect" clinical trial of tirasemtiv in patients with
generalized myasthenia gravis (MG). Tirasemtiv selectively...
Benzinga
Jul 31
Comment
Rodman & Renshaw reiterated an Outperform rating on Cytokinetics (NASDAQ: CYTK) and a target price of $2.
Rodman & Renshaw wrote, “We expect management to provide further details on omecamtiv mecarbil's planned Phase II trials with oral...
Benzinga
Jul 26
Comment
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company and Amgen have reviewed data arising from a recently completed Phase I clinical trial designed to assess the safety, tolerability and pharmacokinetics of modified release...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
